A Phase 3 interventional study of Xuanbai Shengmai Decoction in Acute Respiratory Distress Syndrome (ARDS), sponsored by Southeast University, China. Not yet recruiting. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-06-05.
Sponsored by Southeast University, China · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 24 studies in Respiratory Distress Syndrome by Southeast University, China — 10 open to participants now, 10 under way, 2 of them phase 3. Respiratory Distress Syndrome · Southeast University, China.
Among the 24 studies in Respiratory Distress Syndrome by Southeast University, China, this one is the 3rd largest by planned enrollment of the 11 interventional ones that give a count, is one of 5 that started in 2026, is one of 2 in phase 3, and was the 21st registered.
1,389 studies on the registry are indexed under Respiratory Distress Syndrome; 281 are open to participants now.
Browse Respiratory Distress Syndrome studies →10 of the 24 studies in Respiratory Distress Syndrome by Southeast University, China are open now, in 1 country. Recruiting first, the newest first:
Southeast University, China · Sites in China
Southeast University, China · Sites in China
Ages 18+
Southeast University, China · Sites in China
Ages 18+
Southeast University, China · Sites in China
Ages 18+
Southeast University, China · Sites in China
Ages 18+
By country, each count listing its studies:
Of the 196 Respiratory Distress Syndrome studies recruiting now, 116 (59%) set no upper age limit and 50 (26%) stop at 75 or younger; 52 take children under 18; 9 take healthy volunteers.
This study: 18 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
24 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 5 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 308 is above the median of 60 across 823 interventional studies indexed under Respiratory Distress Syndrome.
Median enrollment 93 across the 11 interventional studies, 134 across the 13 observational. Of the 6 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Southeast University, China is the lead sponsor of 169 studies on the registry; 46 are open to participants now.
3 of the studies in Respiratory Distress Syndrome by Southeast University, China that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07528196Phase 3Southeast University, ChinaStudy of Xuanbai Shengmai Decoction in the Treatment of Acute Respiratory Distress Syndrome | 2027-06 |
| NCT07289711Southeast University, ChinaValidation and Precision Treatment of Inflammatory Subphenotypes in Acute Respiratory Distress Syndrome: A Multicenter Cohort Study | 2026-12-31 |
| NCT06919484Southeast University, ChinaThe Physiological Effect of RCexp on Ventilation/Perfusion Distribution | 2026-12-31 |
Add all 3 to your calendar (.ics) → With an account.
Among the 24 studies in Respiratory Distress Syndrome by Southeast University, China, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Acute respiratory distress syndrome (ARDS) is a common clinical syndrome in the ICU characterized by extremely high mortality and complex pathogenesis.At present, research on individualized treatment, phenotypic differences, and therapeutic efficacy in ARDS has become a hotspot.As characterized by syndrome differentiation, traditional Chinese medicine (TCM) treatment emphasizes interindividual heterogeneity and personalized management, which is expected to serve as a breakthrough in multi-target immune regulation for ARDS. The primary objective of the study is to investigate the effect of Xuanbai Shengmai Decoction on the prognosis of patients with ARDS in a prospective randomized controlled trial. The secondary objective is to evaluate the safety of Xuanbai Shengmai Decoction in the treatment of patients with ARDS.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients in the control group will receive standard comprehensive Western medical treatment.
Patients in the treatment group will receive Xuanbai Shengmai Decoction via oral administration or nasogastric feeding on the basis of standard comprehensive Western medical treatment. The decoction will be administered within 24 hours after enrollment, one dose per day divided into two administrations, for a total treatment duration of 7 days.
Drug: Xuanbai Shengmai Decoction
Patients in the treatment group will receive Xuanbai Shengmai Decoction orally or via nasogastric gavage on the basis of standard comprehensive Western medical treatment. The decoction will be administered within 24 hours after enrollment, one dose per day in two divided administrations, for a total of 7 days.
28-day mortality
Mortality was calculated on day 28 of treatment.
Time frame: On day 28 of treatment
Clinical scoring indicator: LIS
Clinical scores were assessed before treatment, on day 3 of treatment, and on day 7 of treatment.
Time frame: Before treatment,on day 3 of treatment,on day 7 of treatment
Inflammatory indicator: Interleukin-6 (IL-6,pg/mL)
Serum IL-6 levels (pg/mL) are measured at baseline, Day 3, and Day 7 as a marker of systemic inflammatory response.
Time frame: Before treatment,on day 3 of treatment,on day 7 of treatment
Pulmonary vascular permeability indicator: Serum angiopoietin-2 (Ang-2,pg/mL)
The concentration of angiopoietin-2 in peripheral blood (pg/mL) will be measured at baseline (pre-treatment), Day 3, and Day 7 of treatment, as a biomarker of pulmonary vascular permeability.
Time frame: Before treatment,on day 3 of treatment,on day 7 of treatment
Lung injury indicator:Oxygenation index (PaO₂/FiO₂ ratio)
Arterial blood gas samples will be collected at baseline (pre-treatment), Day 3, and Day 7 of treatment to determine the ratio of arterial partial pressure of oxygen (PaO₂) to the fraction of inspired oxygen (FiO₂), which will be used to assess the patient's oxygenation status.
Time frame: Before treatment,on day 3 of treatment,on day 7 of treatment
Ventilator parameter: Tidal volume (VT, mL)
The ventilator-set tidal volume (in mL) will be recorded directly from the ventilator interface at baseline (pre-treatment), Day 3, and Day 7 of treatment.
Time frame: Before treatment,on day 3 of treatment,on day 7 of treatment
Duration of mechanical ventilation
Duration of mechanical ventilation within 28 days
Time frame: within 28 days
Length of ICU stay
Time of staying in ICU within 28 days
Time frame: within 28 days
Multiplex detection:Pathogen Load by Multiplex PCR
Throat swabs, fecal samples (10g), and peripheral blood (3mL) will be collected at baseline, day 3, and day 7 of treatment. Multiplex PCR will be performed to detect the nucleic acid load of target pathogens, with the unit of copies/mL, to evaluate changes in infection burden.
Time frame: Before treatment,on day 3 of treatment,on day 7 of treatment
Clinical scoring indicator:Acute Physiology and Chronic Health Evaluation Ⅱ (APACHE Ⅱ) score
Assessed using the full APACHE Ⅱ scale at baseline (pre-treatment), Day 3, and Day 7 of treatment. The scale consists of three components: acute physiology score, age score, and chronic health evaluation score, with a total score ranging from 0 to 71. Higher scores indicate greater severity of illness and higher risk of mortality.
Time frame: Before treatment,on day 3 of treatment,on day 7 of treatment
Clinical scoring indicators: Sequential Organ Failure Assessment (SOFA) score
Assessed using the full Sequential Organ Failure Assessment scale at baseline (pre-treatment), day 3, and day 7 of treatment. The score evaluates the function of six organ systems: respiratory, coagulation, hepatic, cardiovascular, neurological, and renal, with a total range of 0-24. Higher scores indicate more severe organ dysfunction and a worse prognosis.
Time frame: Before treatment,on day 3 of treatment,on day 7 of treatment
Lung injury indicator:Static lung compliance( mL/cmH₂O)
Static lung compliance ( mL/cmH₂O) will be calculated via the ventilator monitoring platform under constant tidal volume and plateau pressure conditions at baseline (pre-treatment), Day 3, and Day 7 of treatment, to assess respiratory mechanics function.
Time frame: Before treatment,on day 3 of treatment,on day 7 of treatment
Lung injury indicator:Serum soluble receptor for advanced glycation end products (sRAGE,pg/mL)
Peripheral blood samples will be collected at baseline (pre-treatment), Day 3, and Day 7 of treatment to measure serum sRAGE levels (pg/mL), which serves as a biomarker of pulmonary epithelial injury.
Time frame: Before treatment,on day 3 of treatment,on day 7 of treatment
Lung injury indicator:Electrical impedance tomography (EIT) parameters of lung ventilation
Lung ventilation distribution will be monitored by EIT at baseline (pre-treatment), Day 3, and Day 7 of treatment to assess lung injury-related indicators including lung collapse, overdistension, and ventilation inhomogeneity.
Time frame: Before treatment,on day 3 of treatment,on day 7 of treatment
Ventilator parameter:Pressure support (PS, cmH₂O)
The pressure support level provided by the ventilator (in cmH₂O) will be recorded directly from the ventilator interface at baseline (pre-treatment), Day 3, and Day 7 of treatment.
Time frame: Before treatment,on day 3 of treatment,on day 7 of treatment
Ventilator parameter:Positive end-expiratory pressure (PEEP, cmH₂O)
The positive airway pressure maintained at the end of expiration (in cmH₂O) will be recorded directly from the ventilator interface at baseline (pre-treatment), Day 3, and Day 7 of treatment.
Time frame: Before treatment,on day 3 of treatment,on day 7 of treatment
Ventilator parameter:Fraction of inspired oxygen (FiO₂, %)
The fraction of inspired oxygen set on the ventilator (in %) will be recorded directly from the ventilator interface at baseline (pre-treatment), Day 3, and Day 7 of treatment.
Time frame: Before treatment,on day 3 of treatment,on day 7 of treatment
Pulmonary vascular permeability indicator: Lung ultrasound B-line score
The number and distribution of B-lines are assessed and scored by lung ultrasound at baseline (pre-treatment), Day 3, and Day 7 of treatment. A higher number and more diffuse distribution of B-lines indicate more severe pulmonary edema. This score is used to evaluate pulmonary vascular permeability and the severity of pulmonary edema.
Time frame: Before treatment,on day 3 of treatment,on day 7 of treatment
Inflammatory indicator:Tumor necrosis factor-α (TNF-α,pg/mL)
Serum TNF-α levels (pg/mL) are measured at baseline, Day 3, and Day 7 as a marker of systemic inflammatory response.
Time frame: Before treatment,on day 3 of treatment,on day 7 of treatment
Inflammatory indicator:C-reactive protein (CRP,mg/L)
Serum CRP levels (mg/L) are measured at baseline, Day 3, and Day 7 as a marker of systemic inflammatory response.
Time frame: Before treatment,on day 3 of treatment,on day 7 of treatment
Inflammatory indicator:Procalcitonin (PCT,ng/mL)
Serum PCT levels (ng/mL) are measured at baseline, Day 3, and Day 7 as a marker of systemic inflammatory response.
Time frame: Before treatment,on day 3 of treatment,on day 7 of treatment
Microecology:Gut Microbiota Alpha Diversity (Shannon Index)
Fecal samples (10g) will be collected at baseline, day 3, and day 7 of treatment. 16S rRNA high-throughput sequencing will be performed to analyze gut microbiota alpha diversity (Shannon index, unitless) to evaluate changes in intestinal microecological homeostasis.
Time frame: Baseline, Day 3, Day 7 of treatment
Metabolomics analysis:Serum Target Metabolite Concentration
Peripheral blood (3mL) will be collected at baseline, day 3, and day 7 of treatment. Untargeted metabolomics will be performed to detect the concentration of target serum metabolites, with the unit of μmol/L, to evaluate changes in the body's metabolic status.
Time frame: Baseline, Day 3, Day 7 of treatment
No study locations are listed for this record.
Start is estimated for Aug 2026; primary completion for Jun 2027, 10 months later.
Of 39 phase 3 interventional studies under Respiratory Distress Syndrome, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 46. This study's planned 10 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Respiratory Distress Syndrome →